[go: up one dir, main page]

WO2009004057A3 - Mutated dimeric prolactin receptor ligands - Google Patents

Mutated dimeric prolactin receptor ligands Download PDF

Info

Publication number
WO2009004057A3
WO2009004057A3 PCT/EP2008/058589 EP2008058589W WO2009004057A3 WO 2009004057 A3 WO2009004057 A3 WO 2009004057A3 EP 2008058589 W EP2008058589 W EP 2008058589W WO 2009004057 A3 WO2009004057 A3 WO 2009004057A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimeric
mutated
receptor ligands
prolactin receptor
prolactin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/058589
Other languages
French (fr)
Other versions
WO2009004057A2 (en
Inventor
Wang Lingyun
Zhang Jinchao
Leif Christensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/007863 external-priority patent/WO2008028684A2/en
Priority claimed from PCT/EP2008/052784 external-priority patent/WO2009003732A2/en
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2009004057A2 publication Critical patent/WO2009004057A2/en
Publication of WO2009004057A3 publication Critical patent/WO2009004057A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.
PCT/EP2008/058589 2007-07-05 2008-07-03 Mutated dimeric prolactin receptor ligands Ceased WO2009004057A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP07111799.8 2007-07-05
EP07111799 2007-07-05
EPPCT/EP2007/007863 2007-09-10
PCT/EP2007/007863 WO2008028684A2 (en) 2006-09-08 2007-09-10 Peptides with high affinity for the prolactin receptor
EP08101600.8 2008-02-13
EP08101600 2008-02-13
EP08102381.4 2008-03-07
EP08102381 2008-03-07
PCT/EP2008/052784 WO2009003732A2 (en) 2007-07-05 2008-03-07 Peptides with high affinity for the prolactin receptor
EPPCT/EP2008/052784 2008-03-07

Publications (2)

Publication Number Publication Date
WO2009004057A2 WO2009004057A2 (en) 2009-01-08
WO2009004057A3 true WO2009004057A3 (en) 2009-09-03

Family

ID=39869671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/058589 Ceased WO2009004057A2 (en) 2007-07-05 2008-07-03 Mutated dimeric prolactin receptor ligands

Country Status (1)

Country Link
WO (1) WO2009004057A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02142479A (en) * 1988-11-24 1990-05-31 Agency Of Ind Science & Technol Novel recombinant plasmid pprlh4
US20010016569A1 (en) * 1996-11-05 2001-08-23 Smithkline Beecham Corporation Receptor ligands
US20050250689A1 (en) * 2002-12-13 2005-11-10 Brooks Charles L Antagonists for human prolactin
WO2006010891A2 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02142479A (en) * 1988-11-24 1990-05-31 Agency Of Ind Science & Technol Novel recombinant plasmid pprlh4
US20010016569A1 (en) * 1996-11-05 2001-08-23 Smithkline Beecham Corporation Receptor ligands
US20050250689A1 (en) * 2002-12-13 2005-11-10 Brooks Charles L Antagonists for human prolactin
WO2006010891A2 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOFFIN V ET AL: "Development and potential clinical uses of human prolactin receptor antagonists", ENDOCRINE REVIEWS, BALTIMORE, MD, US, vol. 26, no. 3, 6 April 2005 (2005-04-06), pages 400 - 422, XP002408797 *
LANGENHEIM JOHN F ET AL: "Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.", MOLECULAR ENDOCRINOLOGY (BALTIMORE, MD.) MAR 2006, vol. 20, no. 3, March 2006 (2006-03-01), pages 661 - 674, XP009089441, ISSN: 0888-8809 *

Also Published As

Publication number Publication date
WO2009004057A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2011143318A3 (en) Anti-fgfr2 antibodies
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
EP1874824A4 (en) Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2009090651A3 (en) Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
IL199151A (en) Pyrimidine derivatives, pharmaceutical compositions comprising them, their use in the treatment of cancer and kits comprising them
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
SI2100614T1 (en) Antibody against PDGFR-alpha for use in the treatment of tumours
AU2009278929A8 (en) Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
PT2601961T (en) Compositions comprising lag-3 and therapeutic antibodies and their uses in the treatment of cancer
PH12014502419A1 (en) Specific binding proteins and uses thereof
EP2068925A4 (en) Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008015383A8 (en) Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
EP2590671A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
IL212998A0 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
WO2008089397A3 (en) Adrb2 cancer markers
WO2011041319A8 (en) Specific binding proteins and uses thereof
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
IL201460A0 (en) Phthalazinone derivatives and their use as medicament to treat cancer
PT2101731T (en) Endoxifen for use in the treatment of cancer
IL206189A (en) Compounds for use in the treatment of cancer
WO2009004057A3 (en) Mutated dimeric prolactin receptor ligands
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
IL205218A0 (en) Complexes of trpc domains and sestd1 domains and methods and uses involving the same
WO2009147530A3 (en) Conformation specific antibodies that bind trefoil factors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785911

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08785911

Country of ref document: EP

Kind code of ref document: A2